Spinocerebellar Ataxia

Spinocerebellar ataxia is an umbrella term for a large group of mostly inherited brain disorders that primarily damage the cerebellum (the coordination center) and its connections to the spinal cord and brainstem. The damage causes ataxia, which means unsteady movement and poor coordination of walking, hands, speech, and eye movements. Many SCAs progress slowly over years; some cause additional features such as abnormal eye movements, slurred speech, tremor, spasticity, neuropathy, or problems with thinking and mood. Most SCAs are autosomal-dominant (a single changed gene copy can cause disease), though recessive and X-linked forms exist. “SCA” is followed by a number (SCA1, SCA2, SCA3/Machado-Joseph disease, SCA6, etc.) based on the gene involved. There is currently no cure, but supportive therapies and genetic counseling are important, and targeted trials are ongoing. NINDS+2NCBI+2

Spinocerebellar ataxias are a group of mostly genetic, progressive brain disorders that damage the cerebellum and connected pathways. People develop unsteady walking, poor balance, clumsy hand movements, slurred speech, and abnormal eye movements. There are many sub-types (SCA1, SCA2, SCA3, and others), and symptoms vary by gene. At present, there is no widely approved cure, but rehabilitation and targeted symptom management help, and several medicines are under study. National Ataxia Foundation+3NCBI+3National Organization for Rare Disorders+3

Other names

• Hereditary cerebellar ataxia (broad term that includes SCA families). NCBI

• Autosomal dominant cerebellar ataxia (ADCA) (older classification used for many SCA types). Orpha

• Machado-Joseph disease (MJD) — the historical name for SCA3. NINDS

• Polyglutamine (polyQ) ataxias — a subgroup caused by CAG repeat expansions (e.g., SCA1, 2, 3, 6, 7). ScienceDirect

Types

There are dozens of SCA subtypes; the most frequently discussed autosomal-dominant forms include SCA1, SCA2, SCA3 (Machado-Joseph), SCA6, SCA7, and others. Each type is defined by its gene and has somewhat characteristic features (for example, SCA7 often includes progressive vision problems; SCA6 often presents with “pure” cerebellar ataxia). Classification is gene-based, and new types continue to be added as testing improves. National Ataxia Foundation+1

---

Causes

In SCA, “cause” usually means the underlying gene change. For completeness, I also list important non-SCA causes that can mimic hereditary SCA, because doctors must rule these out during evaluation.

1. CAG repeat expansions (polyQ) in SCA genes — toxic elongated polyglutamine tracts damage cerebellar neurons (e.g., SCA1, SCA2, SCA3, SCA6, SCA7). ScienceDirect

2. Non-polyQ dominant SCA mutations — point mutations or insertions/deletions in genes such as KCNC3, CACNA1A, PRKCG causing cerebellar degeneration. NCBI

3. Recessive ataxia genes that can look like SCA clinically (e.g., SYNE1/SCAR8, AOA1/APTX, AOA2/SETX). National Ataxia Foundation+1

4. X-linked ataxia genes (rare) — inherited through the X chromosome, may present with ataxia plus other neurologic signs. NCBI

5. Mitochondrial DNA mutations — cause multisystem disease with ataxia; must be considered in “hereditary ataxia” workups. NCBI

6. Paraneoplastic cerebellar degeneration — immune attack on cerebellum due to an underlying cancer; mimics rapid “SCA-like” ataxia. BMJ Palliative & Supportive Care

7. Multiple system atrophy–cerebellar type (MSA-C) — sporadic neurodegeneration with cerebellar and autonomic failure; can resemble SCA clinically. BMJ Palliative & Supportive Care

8. Autoimmune ataxia (e.g., anti-GAD antibodies) — immune-mediated cerebellitis; sometimes responsive to immunotherapy. BMJ Palliative & Supportive Care

9. Gluten ataxia — immune reaction to gluten damaging cerebellum; dietary treatment may help in select cases. BMJ Palliative & Supportive Care

10. Alcohol-related cerebellar degeneration — chronic alcohol use injures Purkinje cells, causing gait ataxia. BMJ Palliative & Supportive Care

11. Drug-induced ataxia — phenytoin, lithium, certain chemotherapies and sedatives may cause cerebellar symptoms. Practical Neurology

12. Vitamin deficiencies — B1 (thiamine), B12, E deficiency can cause ataxia or neuropathy with ataxia. Practical Neurology

13. Thyroid disease (hypothyroidism) — can present with ataxia that improves when the thyroid is treated. Practical Neurology

14. Vascular causes — small strokes in the cerebellum or vertebrobasilar insufficiency can present with acute ataxia. Practical Neurology

15. Tumors of the posterior fossa — mass lesions compress cerebellum, leading to imbalance and incoordination. Practical Neurology

16. Infections — post-viral cerebellitis (after varicella, EBV, influenza) can cause subacute ataxia. Practical Neurology

17. Toxic exposures — heavy metals (e.g., mercury) or solvents affecting the cerebellum. Practical Neurology

18. Degenerative disorders overlapping with ataxia — Friedreich ataxia (recessive) or CANVAS (cerebellar ataxia, neuropathy, vestibular areflexia syndrome). Practical Neurology

19. Metabolic disorders — urea cycle, peroxisomal, or lysosomal diseases can include ataxia. NCBI

20. Idiopathic late-onset cerebellar ataxia (ILOCA) — diagnosis of exclusion when no cause is found after thorough testing. BMJ Palliative & Supportive Care

---

Common symptoms

1. Unsteady walk (broad-based gait; veering). People often describe “walking like I’m on a boat.” NINDS

2. Poor balance, especially when standing with feet together or in the dark. NINDS

3. Clumsy hand use — trouble with buttons, keys, writing, or using a phone. NINDS

4. Slurred or scanning speech (dysarthria) — words sound broken or slow. NINDS

5. Eye movement problems — nystagmus (jittery eyes), slow saccades, or difficulty tracking. NINDS

6. Intention tremor — shaking that worsens as the hand approaches a target. NINDS

7. Incoordination of legs and arms — overshooting/undershooting movements. NINDS

8. Difficulty with rapid alternating movements (e.g., flipping palms). NINDS

9. Swallowing problems (dysphagia) in later stages of several SCA types. MedlinePlus

10. Spasticity or stiffness in legs in some subtypes (e.g., SCA1, SCA3). MedlinePlus

11. Peripheral neuropathy symptoms — numbness, tingling, burning, reduced vibration sense. BMJ Palliative & Supportive Care

12. Dizziness or imbalance with head movement — vestibular involvement (e.g., CANVAS). Practical Neurology

13. Fatigue and reduced endurance — effortful walking and speaking. National Organization for Rare Disorders

14. Mood or cognitive changes — slowed processing, executive difficulties in some SCA types. Cleveland Clinic

15. Vision problems — especially SCA7 (retinal degeneration) or from oculomotor control issues. NCBI

---

Diagnostic tests

Doctors combine history, examination, and targeted testing. The aim is to confirm a hereditary SCA vs. a look-alike cause, guide treatment, and inform family risk.

A) Physical examination

1. Gait assessment — walking, heel-toe, tandem. Broad-based or staggering gait suggests cerebellar involvement. NINDS

2. Romberg test — standing with feet together, eyes closed; increased sway indicates sensory or cerebellar balance issues. Practical Neurology

3. Finger-to-nose and heel-to-shin — detects limb ataxia and intention tremor. Practical Neurology

4. Rapid alternating movements (diadochokinesis) — slow or irregular performance supports ataxia. NINDS

5. Ocular motor exam — looking for nystagmus, saccadic slowing (prominent in SCA2), or gaze-evoked nystagmus. National Ataxia Foundation

B) Manual/bedside tests

6. SARA (Scale for the Assessment and Rating of Ataxia) — standardized bedside scale to quantify severity and track progression. Practical Neurology

7. Nine-Hole Peg Test / finger tapping — fine motor speed/coordination measures to follow hand ataxia. Practical Neurology

8. Timed 25-Foot Walk or 10-Meter Walk — simple performance measure of gait speed/balance. Practical Neurology

9. Speech assessment — structured dysarthria evaluation to document rate, articulation, and intelligibility. Practical Neurology

10. Swallow screening — bedside assessment (e.g., water swallow test) to flag aspiration risk. BMJ Palliative & Supportive Care

C) Lab and pathological tests

11. Genetic testing panels for SCA — first-line confirmation for suspected hereditary SCA; includes CAG repeat sizing and sequencing of common genes (SCA1/2/3/6/7 and others). NCBI

12. Metabolic and vitamin labs — B12, vitamin E, thiamine, thyroid, copper, and celiac serologies to find treatable mimics. BMJ Palliative & Supportive Care

13. Autoimmune/paraneoplastic antibody panels — anti-GAD, anti-Yo, anti-Hu, etc., when onset is subacute or atypical. BMJ Palliative & Supportive Care

14. General labs — CBC, CMP, HbA1c, inflammatory markers to screen for systemic contributors to neuropathy or cerebellitis. Practical Neurology

15. CSF analysis (lumbar puncture) when indicated — to assess inflammation or paraneoplastic clues in atypical presentations. Practical Neurology

D) Electrodiagnostic tests

16. Nerve conduction studies and EMG — evaluate co-existing peripheral neuropathy, common in certain ataxias. Practical Neurology

17. EEG — reserved for events suggesting seizures or encephalopathy; not routine for isolated ataxia. Practical Neurology

18. Vestibular testing (e.g., calorics, video head impulse) — helps when dizziness and imbalance suggest vestibular dysfunction (e.g., CANVAS). Practical Neurology

E) Imaging tests

19. Brain MRI — key test. Often shows cerebellar atrophy, sometimes brainstem atrophy (e.g., “hot-cross bun” in MSA-C, not SCA), and helps rule out tumor, stroke, or demyelination. BMJ Palliative & Supportive Care

20. Spinal MRI — if symptoms suggest cord involvement or to exclude compressive causes. Practical Neurology

Non-pharmacological treatments (therapies & others)

1) Coordinative/balance physiotherapy. Regular, goal-directed balance and coordination training improves walking, posture, and confidence. Programs that practice stepping, reaching, and gaze stabilization can reduce ataxia severity scores.

2) Structured home exercise (aerobic vs balance). A 2025 randomized clinical trial found both home high-intensity aerobic and home balance training improved ataxia; programs were safe and practical to run at home.

3) Treadmill or body-weight–supported gait training. Progressive, supervised walking programs can improve gait speed and endurance, and complement balance therapy. (Protocol and rehab literature support this approach.)

4) Exergaming/technology-assisted therapy. Game-based balance and coordination tasks can make practice frequent and engaging; they are often added to standard physiotherapy in ataxia studies.

5) Cerebellar non-invasive brain stimulation (tDCS/tACS). Meta-analysis and randomized studies show small, short-term benefits of cerebellar stimulation added to rehab; effects vary and are not yet routine care.

6) Occupational therapy (OT). OT teaches energy saving, safe transfers, home adaptations, and hand-task strategies (weighted utensils, wrist supports) to maintain daily independence in progressive ataxias.

7) Speech-language therapy for dysarthria. Intensive speech therapy and biofeedback programs can improve intelligibility, voice control, and patient-reported outcomes in progressive ataxia.

8) Swallow therapy and dysphagia management. Early screening with swallow studies, diet texture changes, and exercises lower aspiration risk and maintain nutrition in hereditary ataxias.

9) Nutrition support and PEG when needed. For severe swallowing problems, percutaneous endoscopic gastrostomy (PEG) can safely provide long-term feeding and reduce weight loss and aspiration risk.

10) Falls prevention and home safety. Grab bars, non-slip shoes, canes/walkers, and lighting reduce fall-related injuries; therapists can tailor devices after gait assessment.

11) Vision and oculomotor rehab. Exercises for gaze fixation and compensatory strategies can help reading and mobility when nystagmus or saccadic issues are present.

12) Fatigue management & pacing. Scheduling high-energy tasks earlier in the day, planned rests, and realistic activity goals reduce fatigue’s impact on function.

13) Mental health care. Screening and treatment for anxiety/depression is recommended; mood symptoms are common in chronic neurologic disease and affect quality of life.

14) Caregiver education & support. Teaching safe transfers, nutrition aids, and communication strategies reduces complications and caregiver strain.

15) Genetic counseling. Counseling explains inheritance, testing options, and family planning; it is standard in hereditary ataxias.

16) Community & patient organizations. The National Ataxia Foundation provides education, research updates, and peer support that improve self-management.

17) Disease-specific diet for immune causes (if applicable). In gluten ataxia, a strict gluten-free diet can improve symptoms—even without intestinal disease—so screening is important when immune ataxia is suspected.

18) Combined rehab blocks. Intensive outpatient blocks (followed by supported home programs) can produce durable functional gains.

19) Speech-tech aids. Apps and feedback devices can help control loudness and pitch, supporting clearer speech in degenerative ataxia.

20) Research participation. Clinical trials and registries provide access to new therapies and help the field progress.

---

Drug treatments

⚠️ Important: drug responses vary by SCA subtype. Many medicines below are symptomatic or investigational; dosing must be individualized by a neurologist.

1) Riluzole (glutamate modulator). In a randomized, double-blind trial of hereditary cerebellar ataxias, riluzole improved ataxia scores vs placebo over 8 weeks, suggesting modest symptomatic benefit (e.g., 50 mg twice daily). Nausea, dizziness, and liver enzyme elevation are possible.

2) Troriluzole (prodrug of riluzole; investigational). Designed to enhance brain exposure with once-daily dosing; highlighted in recent overviews and advocacy updates as a late-stage candidate for SCA. Common adverse effects are similar to riluzole. (Regulatory status is evolving.)

3) 4-Aminopyridine (4-AP). For episodic ataxia type 2 (EA2)—a related CACNA1A channel disorder—randomized crossover trials show fewer attacks and better quality of life (e.g., 5–10 mg three times daily). Risks include paresthesias and, rarely, seizures; use is subtype-specific.

4) Acetazolamide. First-line for EA2 to reduce attack frequency (e.g., 125–250 mg two to three times daily). Watch for paresthesias, kidney stones, and metabolic acidosis; benefit is best documented in EA2, not degenerative SCAs.

5) Varenicline (α4β2 nicotinic partial agonist). In an RCT of SCA3, varenicline improved axial/gait SARA subscores over 8 weeks (titrated to 1 mg twice daily). Nausea, vivid dreams, and mood changes are possible; specialist monitoring is needed.

6) Amantadine. Small trials and case series report mixed, short-term improvements in ataxia features (e.g., 100 mg 1–2×/day orally or short IV courses). Side effects can include insomnia and livedo reticularis. Evidence is limited.

7) Baclofen (spasticity). Oral baclofen (5–20 mg up to 3–4×/day) or intrathecal baclofen (ITB) pumps for refractory spasticity relieve painful spasms and improve care; drowsiness and weakness can occur.

8) Tizanidine (spasticity). Alternative or add-on to baclofen (e.g., 2–4 mg up to three times daily), with sedation and dry mouth as common effects; liver monitoring is needed.

9) Clonazepam (myoclonus/oscillopsia). Low-dose clonazepam can reduce myoclonus and nystagmus symptoms; sedation and dependence risks require careful use.

10) Gabapentin or pregabalin (neuropathic pain). Help tingling/burning pain and improve sleep; dizziness and edema are common side effects.

11) SSRIs/SNRIs (mood). Depression and anxiety are common in chronic neurologic illness and respond to standard antidepressants; selection is based on comorbidities and side-effect profiles.

12) Modafinil (fatigue/somnolence). Sometimes used off-label to improve daytime alertness; headache and insomnia are possible. Evidence in SCA is pragmatic.

13) Botulinum toxin (focal dystonia/tremor). Targeted injections can reduce dystonia or action tremor in selected patients; weakness in injected muscles is the main risk.

14) Acetyl-DL-leucine / N-acetyl-L-leucine (investigational). Large crossover RCT (ALCAT) in mixed ataxias found no overall benefit over placebo after 6 weeks, though earlier observational work suggested symptomatic improvement; nausea and headache are uncommon.

15) IVIG, steroids, or other immunotherapy (only for immune-mediated ataxias). When ataxia is autoimmune (e.g., gluten ataxia, anti-GAD), early immunotherapy can stabilize or improve symptoms after proper work-up; not indicated for degenerative SCAs.

16) Levodopa (parkinsonism in some SCAs). If SCA subtype presents with parkinsonism, standard dopaminergic therapy may help slowness and stiffness; nausea and dyskinesia may occur.

17) Propranolol or primidone (tremor). May reduce action tremor in selected patients; monitor for fatigue (β-blockers) or sedation (primidone).

18) Acetylsalicylic acid/antithrombotics (if vascular risks). Used for standard indications in stroke prevention when vascular risks coexist; not disease-modifying for SCA.

19) Symptomatic bowel/bladder treatments. Antimuscarinics, laxatives, or pelvic-floor therapy follow general neurology guidance.

20) Sleep management (e.g., melatonin for REM issues). Address insomnia/circadian issues with sleep hygiene and standard agents to improve daytime function.

---

Dietary molecular supplements

1) Coenzyme Q10 (CoQ10). Primary CoQ10 deficiency can present with ataxia and responds to high-dose CoQ10 (often 5–50 mg/kg/day, titrated). Benefits depend on the gene and early treatment.

2) Vitamin E (α-tocopherol). In ataxia with vitamin E deficiency (AVED, TTPA-related), lifelong high-dose vitamin E can prevent or partially reverse neurologic signs; dosing is guided to keep plasma levels in the high-normal range (e.g., 400–800 IU/day or higher per level).

3) Riboflavin (vitamin B2). Riboflavin transporter deficiency (BVVL/RTD) with ataxia often improves on high-dose riboflavin (ranges 7–60 mg/kg/day in reports), especially when started early.

4) CoQ10 in COQ-gene disorders. Case series show improved ataxia scores after CoQ10 in certain COQ gene defects (e.g., COQ5/COQ8A), again stressing genotype-guided therapy.

5) Targeted gluten-free diet (only for gluten ataxia). A strict gluten-free diet can improve gait and coordination in gluten ataxia; not a general SCA treatment.

6) General nutrition optimization. Adequate protein, fiber, hydration, and micronutrients support energy and reduce constipation; dietitians tailor plans in dysphagia.

7) Thiamine (vitamin B1) for deficiency states. Treat documented deficiency promptly (parenteral if severe), because cerebellar signs can worsen with low B1; this is supportive, not SCA-specific.

8) Omega-3–rich foods. Helpful for cardiovascular health and general brain support, though not disease-modifying in SCA.

9) Calcium and vitamin D (bone health). Reduced mobility increases osteoporosis risk; supplementation follows standard guidelines to prevent fractures.

10) Caution with unproven supplements. Many marketed “ataxia cures” lack evidence or have negative RCTs (e.g., acetyl-DL-leucine showed no overall benefit in a large trial). Discuss all products with your clinician.

---

Immunity-booster / regenerative / stem-cell drugs

1) Immunotherapy (IVIG, corticosteroids) helps immune ataxias—not genetic SCA. When ataxia is autoimmune, early treatment can help; in degenerative SCAs, these therapies do not slow the gene-driven process.

2) Stem-cell therapy remains experimental. There are no approved stem-cell treatments for SCA; outside clinical trials, use is not recommended due to uncertain benefit and risks.

3) Troriluzole (investigational neuroprotection). A late-stage candidate designed to modulate glutamatergic tone; regulatory reviews are ongoing and results will clarify disease-modifying potential.

4) N-acetyl-L-leucine (investigational). Studies across ataxia populations are mixed; one pediatric AT trial reported limited symptomatic benefits in non-motor domains. Not approved for SCA.

5) Non-invasive brain stimulation (adjunctive). Considered adjunct to therapy with small, short-term effects; it is neuromodulation, not a regenerative drug.

6) Lifestyle “immune boosters.” Sleep, vaccination, and nutrition support overall health but do not modify SCA genes; still worthwhile to reduce infections and hospitalizations.

---

Surgeries

1) Deep brain stimulation (DBS) for severe tremor/dystonia. Case reports and series in SCA subtypes (e.g., SCA27, SCA17) show DBS can reduce disabling tremor or dystonia when medicines fail; goals are symptom control and function. It does not stop SCA progression.

2) Intrathecal baclofen (ITB) pump. For refractory spasticity and painful spasms, an implanted pump delivers baclofen to the spinal fluid, improving tone with fewer systemic side effects.

3) PEG feeding tube. For severe dysphagia with weight loss or aspiration, PEG provides safe, long-term nutrition and medications.

4) Spinal fusion for scoliosis (mostly Friedreich ataxia). In ataxia with major scoliosis, surgery may be needed for curve control and comfort; it requires careful peri-operative planning due to cardiopulmonary risks.

5) Orthopedic/assistive procedures. Contracture releases or foot procedures are occasionally used to improve bracing and comfort in complex neuro-orthopedic cases.

---

Prevention tips

1. Early rehab and fall-proofing your home to prevent fractures and head injuries.

2. Vaccinations (flu, COVID-19, pneumonia) to reduce hospitalizations that accelerate deconditioning.

3. Treat dysphagia early to avoid aspiration pneumonia and malnutrition.

4. Strength/balance training 3–5 days/week to preserve mobility.

5. Avoid alcohol and sedatives that worsen coordination.

6. Manage bone health (vitamin D/calcium, weight-bearing as tolerated) to prevent osteoporosis.

7. Footwear and assistive devices matched by a therapist to reduce falls.

8. Regular vision and hearing checks to optimize sensory inputs for balance.

9. Screen mood, sleep, and pain so problems don’t erode rehab gains.

10. Genetic counseling for family planning and early detection of treatable mimics (e.g., AVED, CoQ10 deficiency).

---

When to see a doctor urgently

See your neurologist promptly for rapidly worse balance, choking, weight loss, repeated falls, new severe tremor/dystonia, or sudden changes in speech or vision. Swift review enables swallow protection (including PEG when needed), spasticity rescue options (e.g., ITB), and screening for treatable look-alikes such as immune ataxias or vitamin deficiencies.

---

What to eat & what to avoid

• Emphasize: soft, moist, high-protein foods; ample fluids; and dietitian-guided textures if swallowing is unsafe. For gluten ataxia, follow a strict gluten-free diet with professional support.

• Avoid or limit: alcohol and sedating drugs that worsen balance; dry/crumbly foods (if dysphagic) that raise choking risk; and fad supplements lacking evidence.

• Consider: CoQ10, vitamin E, or riboflavin only when a specific deficiency disorder is confirmed; these targeted therapies can be life-changing in the right diagnosis.

---

Frequently asked questions (FAQ)

1) Is there any cure for SCA right now?
No cure yet. Care focuses on rehab and symptom control, and several drugs are in late-stage trials (e.g., troriluzole).

2) Can exercise really help if the disease is genetic?
Yes. Targeted training improves measurable ataxia scores and walking ability—even in progressive disorders.

3) Should I try brain stimulation?
Cerebellar tDCS/tACS may give small, short-term gains when added to therapy; talk to a specialist center.

4) What about varenicline (Chantix)?
In SCA3, an RCT showed improved axial/gait subscores over 8 weeks; it needs careful monitoring for side effects.

5) Is 4-AP or acetazolamide for me?
They help episodic ataxia type 2 (EA2), not typical degenerative SCAs. Genetic confirmation guides use.

6) Do supplements help?
Only in specific deficiency syndromes (e.g., CoQ10 defects, AVED, riboflavin transporter deficiency)—then they can be highly effective.

7) Can diet fix SCA?
Not in genetic SCAs. But in gluten ataxia, a gluten-free diet can help. Otherwise, aim for safe textures, adequate protein, and hydration.

8) Are stem-cell therapies available?
Not as approved treatments for SCA. Consider only in regulated clinical trials.

9) When do we consider a feeding tube?
When weight loss or aspiration risk persists despite therapy. PEG is safe and protects nutrition/medications.

10) My speech is getting harder to understand—can therapy help?
Yes. Intensive speech programs with home practice improve intelligibility and voice control.

11) What about acetyl-DL-leucine I saw online?
A large RCT found no overall benefit over placebo; avoid self-medicating without your neurologist.

12) Can DBS stop my SCA?
No. DBS may reduce tremor/dystonia in selected cases to improve function; it does not slow disease biology.

13) How often should I exercise?
Most programs use 3–5 days/week of balance/coordination and 2–3 days/week of strength/aerobic work, tailored to fatigue.

14) Should my family get genetic counseling?
Yes—inheritance risks, testing options, and early detection of treatable mimics are discussed there.

15) Where can I learn about trials and trusted information?
Check the National Ataxia Foundation and academic neurology clinics for study listings and reliable education.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 24, 2025.